Pfizer: Analysts' Upgrades, Downgrades - TheStreet

NEW YORK (

TheStreet

) --

CHANGE IN RATINGS

A123 Systems

( AONE) initiated at Barclays with an Equal Weight rating and $18 price target. A123 has the potential to emerge as a category leader in the li-ion battery market. 2010 and 2011 EPS estimates set at -$0.77 and -$0.34.

Flir Systems

(FLIR) - Get Report

rated new Neutral at Goldman. $30 price target. Company is well run, but order activity has been weak in Government Systems.

Google

(GOOG) - Get Report

rated new Neutral at MKM Partners. $570 price target. Stock is already pricing in accelerating global search advertising.

IHS

(IHS)

rated new Overweight at Morgan Stanley. IHS was initiated with an Overweight rating. $62 price target. Company can grow margins and is the most attractively valued stock in its group.

Nanosphere

(NSPH)

price target cut at Credit Suisse. NSPH price target trimmed by a dollar to $7. Estimates lowered through 2012. Maintain Outperform rating.

Palm

( PALM) downgraded at Morgan Stanley from Overweight to Equal-weight. Verizon has not backed the Palm launch with much marketing effort. Estimates also lowered.

STOCK COMMENTS / EPS CHANGES

Chico's FAS

(CHS) - Get Report

estimates raised at FBR through 2011. Company has tight inventory controls and still generates strong comp sales. Outperform rating and $18 price target.

Salesforce.com

(CRM) - Get Report

numbers boosted at FBR. Shares of CRM now seen reaching $75. Estimates also raised, as Service Cloud continues to gain traction.

Concho Resources

(CXO) - Get Report

estimates cut at UBS through 2011. Company is realizing better margins. Buy rating and $55 price target.

Dollar Tree

(DLTR) - Get Report

target, estimate raised at Barclays. DLTR price target jumped to $66 from $64 after 4Q10 numbers beat expectation. 2011 EPS estimate increased to $4.23 from $4.18. Maintain Overweight rating.

Dollar Tree

(DLTR) - Get Report

estimates, target upped at Goldman. DLTR estimates were increased through 2011. Company is realizing higher sales growth. Neutral rating and new $57 price target.

Express Scripts

(ESRX)

numbers increased at Goldman. ESRX estimates were boosted through 2012. Company has strong earnings momentum and improved visibility. Buy rating and new $115 price target.

Entergy

(ETR) - Get Report

target lowered at Morgan Stanley. ETR target was cut to $94. Vermont Yankee is facing re-licensing concerns. Overweight rating.

Garmin

(GRMN) - Get Report

estimates, target increased at Goldman. Shares of GRMN now seen reaching $29. Estimates also raised, because of improving margins and lower taxes. Sell rating.

Merck

(MRK) - Get Report

estimates cut at UBS. MRK estimates were lowered through 2011. Expect higher R&D spending and merger synergies to take longer to materialize. Buy rating and $45 price target.

Microstrategy

(MSTR) - Get Report

estimates lowered at FBR through 2011. Company has healthy demand, but earnings growth may still settle down in the coming quarters. Outperform rating and $120 price target.

Nike

(NKE) - Get Report

added to Conviction Buy List at Goldman. NKE was added to the Conviction Buy list. Company should soon return to better sales and earnings growth. Buy rating and $78 price target.

Pfizer

(PFE) - Get Report

estimates boosted at Morgan Stanley through 2011. Expect higher Prevnar sales, following new FDA approval. Overweight rating and $22 price target.

Transocean

(RIG) - Get Report

estimates lowered at UBS through 2011. More Jackup rigs likely to hit the market and some concerns remain about deepwater. Buy rating and $115 price target.

Saks

(SKS)

estimates, target reduced at Goldman. Shares of SKS now seen reaching $6.80. Estimates also cut, because of higher operating and interest expenses. Neutral rating.

TJX Companies

(TJX) - Get Report

numbers boosted at Goldman. Shares of TJX now seen reaching $46. Estimates also raised, because of higher square footage growth and share buybacks. Buy rating.

This article was written by a staff member of TheStreet.com.